Integral Diagnostics（IDX）株式概要
ヘルスケアサービス会社であるインテグラル・ダイアグノスティックス社は、オーストラリアとニュージーランドの開業医、専門医、関連医療従事者、およびその患者に画像診断サービスを提供している。 詳細
IDX Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Integral Diagnostics Limited 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | AU$2.10 |
| 52週高値 | AU$3.07 |
| 52週安値 | AU$1.91 |
| ベータ | 0.12 |
| 1ヶ月の変化 | 4.48% |
| 3ヶ月変化 | -5.41% |
| 1年変化 | -21.64% |
| 3年間の変化 | -31.15% |
| 5年間の変化 | -59.22% |
| IPOからの変化 | 14.75% |
最新ニュース
ナラティブ更新 • Jun 26
IDX: Trimmed Outlook And Neutral Rating Will Define Near-Term Share Performance
Analysts have trimmed their price target for Integral Diagnostics to A$2.15 from A$2.49, as updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E point to a more balanced risk and reward profile following recent share price performance. What’s in the News for Integral Diagnostics No recent news stories are available for Integral Diagnostics based on the provided sources.
ナラティブ更新 • May 11
IDX: New Leadership And New Clinics Will Support Future Upside
Analysts have trimmed their price target for Integral Diagnostics to A$3.11 from A$3.12 as they factor in a slightly higher discount rate and marginally softer profit margin expectations, while keeping revenue growth assumptions and future P/E largely unchanged. What's in the News New Managing Director and CEO Jason Martinez is scheduled to commence on 6 August 2026, with current Managing Director and CEO Dr Ian Kadish staying on until then to support a smooth leadership transition (Key Developments).ナラティブ更新 • Apr 19
IDX: New Leadership And Clinic Expansion Will Support Future Upside
Analysts have maintained their fair value estimate for Integral Diagnostics at A$3.12 per share. This reflects unchanged views on the discount rate, revenue growth, profit margin and future P/E assumptions, and this stability has resulted in an unchanged price target.ナラティブ更新 • Mar 28
IDX: Merger Synergies And New Sites Will Drive Future Upside
Analysts have nudged their price target on Integral Diagnostics slightly lower to A$3.12 from A$3.13. This reflects minor adjustments to fair value estimates, discount rate assumptions and forward P/E expectations.Recent updates
ナラティブ更新 • Jun 26
IDX: Trimmed Outlook And Neutral Rating Will Define Near-Term Share Performance
Analysts have trimmed their price target for Integral Diagnostics to A$2.15 from A$2.49, as updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E point to a more balanced risk and reward profile following recent share price performance. What’s in the News for Integral Diagnostics No recent news stories are available for Integral Diagnostics based on the provided sources.ナラティブ更新 • May 11
IDX: New Leadership And New Clinics Will Support Future Upside
Analysts have trimmed their price target for Integral Diagnostics to A$3.11 from A$3.12 as they factor in a slightly higher discount rate and marginally softer profit margin expectations, while keeping revenue growth assumptions and future P/E largely unchanged. What's in the News New Managing Director and CEO Jason Martinez is scheduled to commence on 6 August 2026, with current Managing Director and CEO Dr Ian Kadish staying on until then to support a smooth leadership transition (Key Developments).ナラティブ更新 • Apr 19
IDX: New Leadership And Clinic Expansion Will Support Future Upside
Analysts have maintained their fair value estimate for Integral Diagnostics at A$3.12 per share. This reflects unchanged views on the discount rate, revenue growth, profit margin and future P/E assumptions, and this stability has resulted in an unchanged price target.ナラティブ更新 • Mar 28
IDX: Merger Synergies And New Sites Will Drive Future Upside
Analysts have nudged their price target on Integral Diagnostics slightly lower to A$3.12 from A$3.13. This reflects minor adjustments to fair value estimates, discount rate assumptions and forward P/E expectations.ナラティブ更新 • Mar 12
IDX: Merger Synergies And New Sites Will Support Future Upside
Analysts have made a small upward adjustment to their price target for Integral Diagnostics, which now sits slightly higher in A$ terms. This reflects modest tweaks to their fair value, discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations.ナラティブ更新 • Feb 25
IDX: Inorganic Expansion And Merger Synergies Will Drive Future Upside
Analysts have trimmed their price target for Integral Diagnostics from around A$3.36 to about A$3.12, reflecting updated assumptions for slightly lower revenue growth, modestly softer profit margins and a reduced future P/E multiple. What's in the News Management is actively assessing M&A options and continuing to look at inorganic growth, alongside opening 3 new greenfield sites in the last quarter of the financial year in Eastwood Private Hospital (South Australia), Wangaratta (Victoria) and Maroochydore (Queensland), plus a relocation to a new facility in Launceston (Key Developments).ナラティブ更新 • Aug 27
Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success
Despite a sharp reduction in projected revenue growth, the consensus future P/E multiple for Integral Diagnostics has contracted significantly, supporting a higher analyst price target of A$3.34. Valuation Changes Summary of Valuation Changes for Integral Diagnostics The Consensus Analyst Price Target has risen from A$3.12 to A$3.34.
新しいナラティブ • Apr 27
Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success
Synergies from the Capitol Health merger and regulation changes are expected to boost operating margins and revenue for Integral Diagnostics.分析記事 • Feb 28
Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch
Integral Diagnostics Limited ( ASX:IDX ) shareholders that were waiting for something to happen have been dealt a blow...分析記事 • Feb 21
Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...分析記事 • Nov 22
Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being
Key Insights Integral Diagnostics will host its Annual General Meeting on 28th of November Total pay for CEO Ian Kadish...分析記事 • Feb 20
Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year
Integral Diagnostics Limited ( ASX:IDX ) has announced that on 4th of April, it will be paying a dividend ofA$0.025...分析記事 • Dec 14
These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • May 26
Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?
While Integral Diagnostics Limited ( ASX:IDX ) might not be the most widely known stock at the moment, it saw...分析記事 • Feb 28
Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year
Integral Diagnostics Limited ( ASX:IDX ) has announced it will be reducing its dividend payable on the 4th of April to...分析記事 • Feb 25
Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Does the February share price for Integral Diagnostics Limited ( ASX:IDX ) reflect what it's really worth? Today, we...分析記事 • Oct 29
Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why
The performance at Integral Diagnostics Limited ( ASX:IDX ) has been quite strong recently and CEO Ian Kadish has...分析記事 • Sep 13
Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...株主還元
| IDX | AU Healthcare | AU 市場 | |
|---|---|---|---|
| 7D | 2.4% | 3.6% | 2.0% |
| 1Y | -21.6% | -3.4% | 2.4% |
業界別リターン: IDX過去 1 年間で-3.4 % の収益を上げたAustralian Healthcare業界を下回りました。
リターン対市場: IDXは、過去 1 年間で2.4 % のリターンを上げたAustralian市場を下回りました。
価格変動
| IDX volatility | |
|---|---|
| IDX Average Weekly Movement | 3.5% |
| Healthcare Industry Average Movement | 4.6% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 17.1% |
| 10% least volatile stocks in AU Market | 3.9% |
安定した株価: IDX 、 Australian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: IDXの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1967 | 3,000 | Ian Kadish | www.integraldiagnostics.com.au |
ヘルスケアサービス会社であるインテグラル・ダイアグノスティックス社は、オーストラリアとニュージーランドの開業医、専門医、関連医療従事者、およびその患者に画像診断サービスを提供している。磁気共鳴画像、陽電子放射断層撮影、コンピューター断層撮影、マンモグラフィー、インターベンショナル・ラジオロジー、超音波、X線やEOSなどのX線撮影を提供している。インテグラル・ダイアグノスティックス社は1967年に設立され、本社はオーストラリアのメルボルンにある。
Integral Diagnostics Limited 基礎のまとめ
| IDX 基礎統計学 | |
|---|---|
| 時価総額 | AU$782.23m |
| 収益（TTM） | AU$14.03m |
| 売上高(TTM) | AU$767.82m |
55.8x
PER（株価収益率1.0x
P/SレシオIDX は割高か？
公正価値と評価分析を参照収益と収入
| IDX 損益計算書（TTM） | |
|---|---|
| 収益 | AU$767.82m |
| 売上原価 | AU$525.98m |
| 売上総利益 | AU$241.84m |
| その他の費用 | AU$227.82m |
| 収益 | AU$14.03m |
直近の収益報告
Dec 31, 2025
次回決算日
Aug 25, 2026
| 一株当たり利益（EPS） | 0.038 |
| グロス・マージン | 31.50% |
| 純利益率 | 1.83% |
| 有利子負債／自己資本比率 | 50.1% |
IDX の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
3.5%
現在の配当利回り192%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/01 12:03 |
| 終値 | 2026/07/31 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/06/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Integral Diagnostics Limited 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22
| アナリスト | 機関 |
|---|---|
| Thomas Yeo | Barrenjoey Markets Pty Limited |
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Benjamin Brayshaw | Barrenjoey Markets Pty Limited |